Development of a specific substrate—Inhibitor panel (Liver-on-a-chip) for evaluation of cytochrome P450 activity

Bulletin of Experimental Biology and Medicine

Volumn 162, Issue 1, 2016, Pages 170-174

  Zakhariants, A A ^a   Burmistrova, O A ^a   Shkurnikov, M Y ^b   Poloznikov, A A ^a   Sakharov, D A ^a  

^a Biocilicum Research and Production Center   (Russian Federation)

^b P A Herzen Research Oncological Institute   (Russian Federation)

Author keywords

Biotransformation; HepaRG; Liver cell model; Liver on achip; Preclinical in vitro studies

Indexed keywords

2 PHENYL 2 (1 PIPERIDINYL)PROPANE; AMFEBUTAMONE; CYTOCHROME P450; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; KETOCONAZOLE; N BENZYLNIRVANOL; OMEPRAZOLE; PROPANE; SULFAPHENAZOLE; TESTOSTERONE; TOLBUTAMIDE; UNCLASSIFIED DRUG; 2-PHENYL-2-(1-PIPERIDINYL)PROPANE; CYP2B6 PROTEIN, HUMAN; CYP2C19 PROTEIN, HUMAN; CYP2C9 PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; CYTOCHROME P450 INHIBITOR; MEPHENYTOIN; N-3-BENZYLNIRVANOL; PHENCYCLIDINE;

ARTICLE; CATALYSIS; DRUG TRANSFORMATION; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROXYLATION; IN VITRO STUDY; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MASS SPECTROMETRY; NONHUMAN; ANALOGS AND DERIVATIVES; DRUG EFFECTS; ENZYME SPECIFICITY; ENZYMOLOGY; LAB ON A CHIP; LIVER; LIVER MICROSOME; METABOLISM;

BUPROPION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP2B6; CYTOCHROME P-450 CYP2C19; CYTOCHROME P-450 CYP2C9; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME INHIBITORS; HUMANS; KETOCONAZOLE; LAB-ON-A-CHIP DEVICES; LIVER; MASS SPECTROMETRY; MEPHENYTOIN; MICROSOMES, LIVER; OMEPRAZOLE; PHENCYCLIDINE; SUBSTRATE SPECIFICITY; SULFAPHENAZOLE; TESTOSTERONE; TOLBUTAMIDE;

EID: 85028282049     PISSN: 00074888     EISSN: 15738221     Source Type: Journal    
DOI: 10.1007/s10517-016-3567-z     Document Type: Article

References (15)

1. Semenova OV, Petrov VA, Gerasimenko TN, Aleksandrova AV, Burmistrova OA, Khutornenko AA, Osipyants AI, Poloznikov AA, Sakharov DA. Effect of Circulation Parameters on Functional Status of HepaRG Spheroids Cultured in Microbioreactor. Bull. Exp. Biol. Med. 2016;161(3):425-429.
2. Bogaards JJ, Bertrand M, Jackson P, Oudshoorn MJ, Weaver RJ, van Bladeren PJ, Walther B. Determining the best animal model for human cytochrome P450 activities: acomparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica. 2000;30(12):1131-1152.
3. Gervasini G, Martínez C, Agúndez JA, García-Gamito FJ, Benítez J. Inhibition of cytochrome P450 2C9 activity in vitro by 5-hydroxytryptamine and adrenaline. Pharmacogenetics. 2001;11(1):29-37.
4. Gibbs MA, Thummel KE, Shen DD, Kunze KL. Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression. Drug Metab. Dispos. 1999;27(2):180-187.
5. Ha-Duong NT, Marques-Soares C, Dijols S, Sari MA, Dansette PM, Mansuy D. Interaction of new sulfaphenazole derivatives with human liver cytochrome p4502Cs: structural determinants required for selective recognition by CYP 2C9 and forinhibition of human CYP 2Cs. Arch. Biochem. Biophys. 2001 Vol. 394(2):189-200.
6. Komatsu K, Ito K, Nakajima Y, Kanamitsu SI, Imaoka S, Funae Y, Green CE, Tyson C.A, Shimada N, Sugiyama Y. Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments. Drug Metab. Dispos. 2000;28(4):475-481.
7. Langley G, Austin CP, Balapure AK, Birnbaum LS, Bucher JR, Fentem J, Fitzpatrick SC, Fowle JR. 3rd, Kavlock RJ, Kitano H, Lidbury BA, Muotri AR, Peng SQ, Sakharov D, Seidle T, Trez T, Tonevitsky A, van de Stolpe A, Whelan M, Willett C. Lessons from toxicology: developing a 21st-century paradigm for medical research. Environ. Health Perspect. 2015;123(11):A268-A272.
8. Martignoni M, Groothuis GM, de Kanter R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin. Drug Metab. Toxicol. 2006;2(6):875-894.
9. Materne EM, Ramme AP, Terrasso AP, Serra M, Alves PM, Brito C, Sakharov DA, Tonevitsky AG, Lauster R, Marx U. A multi-organ chip co-culture of neurospheres and liver equivalents for long-term substance testing. J. Biotechnol. 2015;205:36-46.
10. Materne EM, Tonevitsky AG, Marx U. Chip-based liver equivalents for toxicity testing-organotypicalness versus costeffi cient high throughput. Lab Chip. 2013;13(18):3481-3495.
11. Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br. J. Clin. Pharmacol. 1998;45(6):525-538.
12. Rasmussen BB, Nielsen TL, Brøsen K. Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. Pharmacol. Toxicol. 1998;83(6):240-245.
13. Suzuki H, Kneller MB, Haining RL, Trager WF, Rettie AE. (+)-N-3-Benzyl-nirvanol and (-)-N-3-benzyl-phenobarbital: new potent and selective in vitro inhibitors of CYP2C19. Drug Metab. Dispos. 2002;30(3):235-239.
14. Walsky RL, Obach RS. A comparison of 2-phenyl-2-(1-piperidinyl) propane (ppp), 1,1’,1”-phosphinothioylidynetrisaziridine (thioTEPA), clopidogrel, and ticlopidine asselective inactivators of human cytochrome P450 2B6. Drug Metab. Dispos. 2007;35(11):2053-2059.
15. Wang H, Tompkins LM. CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Curr. Drug Metab. 2008;9(7):598-610.